Precigen (NASDAQ:PGEN) Raised to “Hold” at Wall Street Zen

Precigen (NASDAQ:PGEN) was upgraded by equities researchers at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued on Saturday.

PGEN has been the topic of several other research reports. Citizens Jmp raised their price objective on shares of Precigen from $8.00 to $9.00 and gave the company a “market outperform” rating in a research report on Thursday. Weiss Ratings reissued a “sell (d-)” rating on shares of Precigen in a research report on Thursday, January 22nd. Zacks Research upgraded shares of Precigen from a “strong sell” rating to a “hold” rating in a report on Tuesday, March 10th. Finally, HC Wainwright lifted their price objective on shares of Precigen from $9.00 to $10.00 and gave the company a “buy” rating in a research note on Thursday. Four investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Precigen presently has a consensus rating of “Hold” and a consensus target price of $9.50.

Precigen Stock Performance

Shares of PGEN stock opened at $3.67 on Friday. Precigen has a fifty-two week low of $1.11 and a fifty-two week high of $5.47. The stock’s 50-day moving average is $4.08 and its two-hundred day moving average is $3.97. The company has a debt-to-equity ratio of 4.46, a current ratio of 3.09 and a quick ratio of 2.83. The firm has a market cap of $1.30 billion, a P/E ratio of -2.74 and a beta of 1.10.

Precigen (NASDAQ:PGEN) last announced its quarterly earnings results on Wednesday, March 25th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.09. The business had revenue of $4.57 million during the quarter, compared to analyst estimates of $8.29 million. Precigen had a positive return on equity of 2,317.96% and a negative net margin of 2,588.21%. Analysts predict that Precigen will post -0.32 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Precigen

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. NBC Securities Inc. acquired a new position in Precigen during the fourth quarter valued at approximately $38,000. Mason Investment Advisory Services Inc. acquired a new stake in shares of Precigen in the fourth quarter worth $42,000. Abel Hall LLC acquired a new stake in shares of Precigen in the fourth quarter worth $44,000. NewEdge Advisors LLC bought a new stake in shares of Precigen during the 4th quarter worth $45,000. Finally, Asempa Wealth Advisors bought a new stake in shares of Precigen during the 4th quarter worth $48,000. 33.51% of the stock is currently owned by institutional investors and hedge funds.

Precigen News Summary

Here are the key news stories impacting Precigen this week:

• Positive Sentiment: HC Wainwright raised multi‑year EPS forecasts (Q3‑2026 to FY2030) and reiterated a Buy rating with a $10 price target, projecting material earnings improvement through 2030 — supportive for longer‑term upside.
• Positive Sentiment: Citizens/JMP lifted its price target to $9 and moved to “market outperform,” adding another near‑term bullish analyst signal. Benzinga coverage
• Positive Sentiment: Management says PAPZIMEOS launch is accelerating with broad U.S. payer coverage and expects Q1 revenue to exceed $18M; company guidance points toward cash‑flow breakeven in 2026 if momentum continues. Precigen expects Q1 revenue to exceed $18M as PAPZIMEOS launch accelerates…
• Positive Sentiment: Analyst write‑ups highlight PAPZIMEOS’s blockbuster potential and model scenarios that imply meaningful upside from current levels, underpinning buy‑side interest. Precigen: The Best Potential Blockbuster You’ve Never Heard Of
• Neutral Sentiment: Q4 earnings materials and call transcripts are available for investors to parse execution details and commercial cadence; management commentary will drive near‑term sentiment. Q4 2025 Earnings Call Transcript
• Neutral Sentiment: Q4 beat on EPS (small) but revenue missed estimates — mixed fundamentals that leave room for both upside on commercial execution and downside if sales growth stalls. Precigen Reports Q4 Loss, Lags Revenue Estimates
• Negative Sentiment: After a roughly 145% one‑year surge, some coverage questions valuation and whether near‑term upside is already priced in — pieces asking “Is it too late?” amplify profit‑taking pressure. Is It Too Late To Consider Precigen (PGEN) After Its 145% One Year Surge?
• Negative Sentiment: High trading volume and short‑term pullback risk: elevated turnover after the rally can accelerate declines if upcoming sales data or payer dynamics disappoint — the main near‑term risk for the stock.

About Precigen

Precigen, Inc (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen’s approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen’s technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.